A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Harmony Biosciences Holdings, Inc. HRMY
Strong broader-coverage candidate · Harmony Biosciences Holdings, Inc.
On FrontierLab's discovery record since 2026-06-23 (15 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Strong" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-10), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 24.3% |
|---|---|
| Gross margin | 75.4% |
| Gross profits / assets | 0.53 |
| Rule of 40 | 48.3 |
| Net margin | 24% |
| Cash runway (months) | — |
| PEG | — |
| Price / sales | 2.5 |
Quality checklist
- ✓ Revenue growth — 24.3% (pass ≥ 20%)
- ✓ Gross profits / assets — 0.53 (pass ≥ 0.33)
- ✓ Gross margin — 75.4% (pass ≥ 60%)
- ✓ Cash generation
- ✓ Share dilution — 0.6%
Fundamentals — snapshot as of 2026-09-10
| Stage | Established |
|---|---|
| Share issuance (YoY) | 0.6% · flat share count |
| Moat | — |
| TAM | — |
| P/E (trailing) | 13.5 |
| EPS (trailing) | $3.08 |
| Burn multiple | — |
| Gross-margin trend (pts) | -2.9 |
| Cash / assets | 0.49 |
| Net debt / EBITDA | -1.4 |
| Statements as of | Q2 FY2026 · filed 2026-08-04 |
Momentum context — a snapshot from 2026-09-10, not current
| Price at surface | $41.62 (as of 2026-09-10) |
|---|---|
| 52-week range | $25.52 – $43.49 |
| % off 52-wk high | -4.3% |
| RSI (14) | 62 |
| Relative volume | 1.5× |
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-09-10 (end-of-day). How grades are computed →